Zacks Industry Outlook McKesson, Cardinal, West Pharmaceutical, Align and Henry
McKesson, Cardinal, West Pharmaceutical, Align and Henry have been highlighted in this Industry Outlook article.
HSIC - Henry Schein, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$87.13
DETAILS
HIGH:
$100.00
LOW:
$64.00
MEDIAN:
$86.00
CONSENSUS:
$87.13
DOWNSIDE:
0.79%
Stock News
5 Medical Supply Stocks to Buy Amid Strong Industry Tailwinds
Here, we highlight five dental supplies stocks, MCK, CAH, WST, ALGN and HSIC, which are well positioned to generate wealth for investors amid improving industry prospect.
Is Henry Schein (HSIC) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
GoTu and Henry Schein Announce Strategic Partnership to Strengthen Dental Workforce Support Nationwide
MIAMI, June 30, 2026 /PRNewswire/ -- GoTu Technology, the nation's leading dental talent marketplace, and Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced a new strategic partnership designed to help dental practices address ongoing staffing challenges and maintain continuity of patient care. Through this collaboration between GoTu and Henry Schein Dental Recruitment Services (a division of Henry Schein Financial Enterprises, LLC, a wholly-owned subsidiary of Henry Schein), dental practices will gain expanded access to GoTu's technology-enabled platform, which connects offices with qualified dental hygienists, dental assistants, and associate dentists for both temporary and permanent staffing needs.
Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Henry Schein: Smile Because The Upside Isn't Over
Henry Schein remains a dominant global provider in dental and medical practitioner supplies, with strong market shares and ongoing revenue growth. HSIC's Q1 2026 revenue grew 6.3% year-over-year, driven by robust global dental merchandise and equipment demand, particularly in aging and expanding populations. Profitability metrics are mixed, but adjusted net income and EBITDA are rising; management guides for 3–5% revenue growth and mid-single-digit EBITDA growth in 2026.
This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Here Are Thursday’s Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, Toast, and More
Pre-Market Stock Futures: Futures are trading higher after a dreadful day on Wall Street, when all the major indices traded lower, and we saw the same pattern that has developed over the last week. The "Buy the Dip" traders come in, briefly get an uptick, and a move higher, and the sellers swarm in to... Here Are Thursday's Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, Toast, and More
Why Is Henry Schein (HSIC) Up 4.6% Since Last Earnings Report?
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?
Henry Schein Sees Steady Dental Demand, $125M Profit Lift by 2026
Henry Schein NASDAQ: HSIC executives said the company is on track with its 2026 commitments and value-creation plan, while pointing to continued momentum in the U.S. dental market despite broader concerns about consumer confidence.
Here's Why Henry Schein (HSIC) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is This the Right Time to Keep HSIC Stock in Your Portfolio?
Henry Schein is backed by a dental and medical distribution scale, digital dentistry push and acquisitions, but debt and macro headwinds weigh on its outlook.
Henry Schein, Inc. (HSIC) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Henry Schein, Inc. (HSIC) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Here's Why Henry Schein (HSIC) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Henry Schein Announces the Election of William K. “Dan” Daniel as Independent Chairman of the Board
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary c.
Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness
Henry Schein NASDAQ: HSIC executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season.
Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth
Henry Schein One, the global leader in dental technology, today announced the release of its [url="]2026 Catalyst Index[/url], the fifth edition of its annual
Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth
AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking report analyzing performance across tens of thousands of DSOs, multi-location organizations, and private practices. This year's data points to a clear and urgent shift for the industry: in a slower economy, growth is no longer determined by scale or efficiency alone; it is driven by clinical execution.
Henry Schein, Inc. (HSIC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Henry Schein, Inc. (HSIC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Here's Why Henry Schein (HSIC) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Price Targets
Henry Schein initiated with a Market Perform at BMO Capital
$85.00
(was $83.22)
Vik Chopra
·
BMO Capital
BTIG upgrades Henry Schein to Buy on 'healthy' dental markets
$100.00
(was $78.85)
BTIG
Henry Schein price target lowered to $85 from $87 at UBS
$85.00
(was $74.35)
Kevin Caliendo
·
UBS
Henry Schein price target lowered to $82 from $88 at Mizuho
$82.00
(was $74.37)
Mizuho Securities
Henry Schein price target lowered to $97 from $104 at Baird
$97.00
(was $74.37)
Robert W. Baird
Henry Schein price target raised to $64 from $61 at Morgan Stanley
$64.00
(was $78.22)
Erin Wright
·
Morgan Stanley
Henry Schein price target raised to $97 from $79 at Barrington
$97.00
(was $81.60)
Barrington
Henry Schein price target raised to $87 from $75 at Leerink
$87.00
(was $83.35)
Leerink Partners
Henry Schein upgraded to Outperform from Neutral at Baird
$100.00
(was $79.57)
Robert W. Baird
Henry Schein price target raised to $81 from $74 at Mizuho
$81.00
(was $79.98)
Steven Valiquette
·
Mizuho Securities
Henry Schein initiated with an Overweight at Barclays
$86.00
(was $72.86)
Barclays
Henry Schein price target raised to $90 from $83 at Evercore ISI
$90.00
(was $71.69)
Evercore ISI
Henry Schein price target raised to $79 from $78 at Barrington
$79.00
(was $71.32)
Barrington
Henry Schein upgraded to Outperform from In Line at Evercore ISI
$83.00
(was $69.04)
Evercore ISI
Henry Schein price target raised to $75 from $69 at Leerink
$75.00
(was $70.81)
Michael Cherny
·
Leerink Partners
Henry Schein price target lowered to $86 from $90 at Barrington
$86.00
(was $66.24)
Michael Petusky
·
Barrington
CFRA Downgrades Henry Schein (HSIC) to Sell ,'see better near-term upside in pharmaceutical distributors'
$67.00
(was $71.10)
Daniel Rich
·
CFRA
Henry Schein price target raised to $74 from $70 at Evercore ISI
$74.00
(was $69.30)
Elizabeth Anderson
·
Evercore ISI
Baird Upgrades Henry Schein (HSIC) to Outperform
$92.00
(was $70.34)
Jeff Johnson
·
Robert W. Baird
Henry Schein Gears Up For Q3 Print; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts
$70.00
(was $64.07)
Jonathan Block
·
Stifel Nicolaus